Welcome to our dedicated page for Collegium Pharmaceutical SEC filings (Ticker: COLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Collegium Pharmaceutical, Inc. (Nasdaq: COLL) provides access to the company’s official regulatory submissions as a public biopharmaceutical issuer. These documents, filed with the U.S. Securities and Exchange Commission, offer detailed information on Collegium’s financial condition, risk factors, capital structure, and governance as it advances a portfolio of pain management medications and ADHD-focused neuropsychiatry products.
Investors and analysts can use this page to review periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, key products, and risk environment, and present audited or reviewed financial statements. Current reports on Form 8-K, like those cited in recent disclosures, furnish information on material events, including quarterly financial results, earnings presentations, share repurchase authorizations, and other significant corporate actions.
For those examining executive and board matters, proxy statements on Schedule 14A and related filings provide context on governance and compensation policies. Filings related to securities offerings and credit facilities can shed light on how Collegium finances its operations and business development plans, including the use of syndicated credit arrangements and other debt instruments mentioned in company press releases.
In addition, users can monitor beneficial ownership and insider activity through forms such as Form 4, which report transactions in Collegium’s common stock by directors, officers, and certain shareholders. Understanding these filings can help readers interpret how management and insiders interact with COLL shares over time.
On Stock Titan, SEC documents for Collegium are updated as they become available from EDGAR. AI-powered tools can help summarize lengthy filings, highlight key sections on product portfolios, non-GAAP metrics, and risk factors, and make it easier to navigate complex disclosures when researching COLL as an investment or analyzing its regulatory history.
COLLEGIUM PHARMACEUTICAL, INC. executive vice president and general counsel David Dieter reported an open-market sale of 13,976 shares of common stock on March 18, 2026 at a weighted average price of $34.9241 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, and executed through multiple trades between $34.74 and $35.39. Following this transaction, Dieter directly holds 77,071 shares of Collegium common stock.
Collegium Pharmaceutical plans to acquire AZSTARYS, an ADHD medicine, for $650 million in cash, plus up to $135 million in potential regulatory and commercial milestone payments. The deal will give Collegium full ownership of entities holding AZSTARYS and is expected to close in the second quarter of 2026, subject to customary conditions including Hart-Scott-Rodino clearance.
The transaction is funded by about $350 million of cash on hand and a previously announced $300 million delayed draw term loan, with net debt to adjusted EBITDA projected around 2x at closing. Collegium expects AZSTARYS to generate more than $50 million of pro forma net revenue in the second half of 2026, deliver over $50 million in annual run-rate synergies within 12 months of close, and be immediately accretive to adjusted EBITDA. Patent protection for AZSTARYS is expected to extend into 2037, strengthening Collegium’s ADHD franchise alongside JORNAY PM and further diversifying revenue beyond its pain portfolio.
Fidelity Brokerage Services LLC submitted a Form 144 reporting an intended sale of 13,976 shares of Common Stock (NASDAQ) tied to restricted stock vesting on 03/17/2026.
The filing also discloses a prior sale by David Dieter of 6,224 shares on 03/09/2026 for $228,109.60. The notice lists the broker and identifies the shares as compensation-related.
Collegium Pharmaceutical EVP & General Counsel David Dieter sold 6,224 shares of common stock at $36.65 per share in an open-market transaction. After this sale, he directly holds 91,047 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating it was scheduled in advance rather than timed discretionarily.
COLLEGIUM PHARMACEUTICAL, INC executive Scott Dreyer, EVP & Chief Commercial Officer, reported open-market sales of the company’s common stock. On March 3, 2026, he sold 46,417 shares at a weighted average price of $40.3636 per share and 3,559 shares at a weighted average price of $40.9889 per share.
These sales, totaling 49,976 shares, were effected pursuant to a Rule 10b5-1 trading plan adopted by Dreyer on September 3, 2025. After the reported transactions, he held 71,770 shares of common stock directly.
COLL filed a Form 144 reporting a proposed sale of 49,976 common shares tied to restricted stock vesting on 02/10/2026. The filing also records a prior disposition of 17,600 common shares by Scott Dreyer on 12/08/2025 for $847,855.36. The form lists 31,753,211 shares outstanding as of 03/03/2026.
Collegium Pharmaceutical files its annual report describing a diversified pain and ADHD portfolio and a heavily regulated operating environment. The company markets Xtampza ER, Belbuca, Symproic, the Nucynta Products, and ADHD drug Jornay PM in the United States.
The September 2024 acquisition of Ironshore added Jornay PM and expanded Collegium into neuropsychiatry. As of June 30, 2025, non-affiliate common stock held an aggregate market value of about $926.4 million, and as of January 31, 2026 there were 31,753,211 common shares outstanding.
The filing highlights extensive opioid and stimulant regulation, REMS obligations, DEA quota controls, and broad healthcare fraud and abuse laws. It also notes patent and exclusivity timelines, looming generic competition for Nucynta, and growing policy pressure on U.S. drug pricing and reimbursement.
Collegium Pharmaceutical reported strong fourth-quarter and full-year 2025 results, led by its ADHD drug Jornay PM and its pain portfolio. Q4 2025 product revenues, net were $205.4 million, up 13% year-over-year, and adjusted EBITDA reached $127.3 million, up 18%.
For full-year 2025, product revenues, net grew to $780.6 million from $631.4 million, a 24% increase, while adjusted EBITDA rose to $460.5 million, up 15%. Jornay PM net revenue was $148.9 million, up 48%, and the pain portfolio delivered $631.7 million, up 6%.
GAAP net income for 2025 was $62.9 million (diluted EPS $1.73), down from $69.2 million in 2024, while non-GAAP adjusted net income increased to $289.3 million (adjusted EPS $7.42). The company generated $329.3 million in cash from operations and ended 2025 with $386.7 million in cash, cash equivalents and marketable securities. A new $980 million syndicated credit facility refinanced prior debt and is expected to lower interest costs. Collegium reaffirmed its 2026 guidance, including product revenues, net of $805–$825 million and adjusted EBITDA of $455–$475 million.
Rubric Capital Management LP and David Rosen filed an amended Schedule 13G/A reporting beneficial ownership of 1,496,436 shares of Collegium Pharmaceutical common stock. This represents 4.73% of the class, based on 31,610,976 shares outstanding as of October 31, 2025.
The shares are held for investment by funds advised by Rubric Capital, with shared voting and dispositive power and no sole voting or dispositive power. The filers certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Collegium.